INDO US BIO-TECH

Ahmedabad, India Founded: 2004 • Age: 22 yrs Listed
Producer and supplier of seeds
Request Access
Report Incorrect Data
Page last updated

About INDO US BIO-TECH

INDO US BIO-TECH is a publicly listed company based in Ahmedabad (India) founded in 2004 by Jagdish Ajudiya. Producer and supplier of seeds. The company has 22 employees. Its Indian entity Indo Us Bio-Tech Limited reported revenue of ₹110 Cr. INDO US BIO-TECH offers products and services including Tomato Seeds, Okra Seeds, Cotton Seeds, Cucumber Seeds, and Wheat Seeds. Its focus areas include Food and Agriculture Tech, Crop Tech, Farm Inputs and Seeds. Its competitors include Mahyco and Nuziveedu Seeds; 2 of its 2 listed competitors have raised funding.

Company details

Founded in 2004 in Ahmedabad, India, the company operates in the agriculture sector, focusing on seeds. Research and development, production, marketing, and sales of vegetable seeds, cotton seeds, oilseeds, spice seeds, pulse seeds, and cereal seeds are conducted. Farming guidelines, practices, pest and disease control demonstrations, and fertilizer application advice are also provided to support agricultural activities.

  • Headquarters Ahmedabad, India
  • Employees 22
  • Founders Jagdish Ajudiya
  • Stage Public
  • Sectors
    Agriculture
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website indousagriseeds.com
  • Social LinkedIn X Facebook YouTube
  • Legal Name Indo Us Bio-Tech Ltd.
Operational Areas
Agriculture → Crop Tech & Equipment
Key Metrics
  • Market Cap
    ₹134 Cr

    INDOUS · NSE

  • Share Price
    ₹65.56

    -2.24% today

  • Revenue
    ₹50.06 Cr

    FY 2021-22 · +24.8% YoY

  • EBITDA
    ₹6.79 Cr

    Margin 13.6%

  • Net Profit
    ₹5.06 Cr

    FY 2021-22 · +3.3% YoY

  • P/E (TTM)
    77.0x

    P/B 8.7x

  • ROE
    16.9%

    ROCE 15.1%

  • Debt / Equity
    0.41

    Interest cover 19.0x

  • Employee Count
    22

Products & Services of INDO US BIO-TECH

INDO US BIO-TECH offers a comprehensive portfolio of products and services, including Tomato Seeds, Okra Seeds, Cotton Seeds, Cucumber Seeds, and Wheat Seeds.

Tomato Seeds
Vegetable Seeds

Hybrid seeds for disease-resistant tomato cultivation

Okra Seeds
Vegetable Seeds

Hybrid seeds for high-yield okra farming

Cotton Seeds
Fiber Crop Seeds

Hybrid cotton seeds resistant to pests

Cucumber Seeds
Vegetable Seeds

Hybrid seeds for climate-adaptable cucumber growth

Wheat Seeds
Cereals Seeds

Hybrid seeds for improved wheat production

Apps and channels of INDO US BIO-TECH

its YouTube channel INDO US BIO-TECH LIMITED has 158 subscribers and 30 videos.

INDO US BIO-TECH LIMITED
YouTube 158 subscribers 30 videos Science & Technology
Open channel

Videos from INDO US BIO-TECH

The most watched videos on INDO US BIO-TECH's YouTube channel, INDO US BIO-TECH LIMITED (158 subscribers). Click a video to play it here.

INDO US BIO-TECH LIMITED(INDOUS AGRISEEDS) CORPORATE MOVIE. Our vision
1.5K views
INDO US BIO-TECH LIMITED IPO
884 views
INDOUS 999+
666 views
INDOUS BIOTECH LIMITED
556 views

More on INDO US BIO-TECH LIMITED.

Board of directors of Indo Us Bio-Tech Limited (INDO US BIO-TECH)

Indo Us Bio-Tech Limited is the primary company behind INDO US BIO-TECH. The board of Indo Us Bio-Tech Limited currently have 6 directors; the longest-serving is Jagdishkumar Devjibhai Ajudiya, appointed in 2004. 8 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Jagdishkumar Devjibhai Ajudiya
DIN 01745951
Managing Director04 Feb 200422 yrs 9 moIndo Us Bio-Tech Limited
Malti Jagdishbhai Ajudia
DIN 02403878
Whole-time director01 Nov 200818 yrsIndo Us Bio-Tech Limited
Priyanka Samarth Patel
DIN 07941023
Director23 Nov 20178 yrs 11 moIndo Us Bio-Tech Limited
Ritaben Nileshbhai Kikani
DIN 08367656
Director01 Mar 20197 yrs 8 moIndo Us Bio-Tech Limited
Shilpa Chetanbhai Thumar
DIN 09259942
Director05 Aug 20215 yrs 3 moIndo Us Bio-Tech Limited
Hemanshi Darsh Soni
DIN 11659183
Director21 Apr 20266 moIndo Us Bio-Tech Limited

People of INDO US BIO-TECH

1 people are tracked at INDO US BIO-TECH (1 in leadership); the tracked headcount is 22.

NameRoleGroup
Jagdish Ajudiya
Founder & Managing DirectorLeadership
Premium access

Complete people profiles for INDO US BIO-TECH

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of INDO US BIO-TECH

INDO US BIO-TECH is a publicly listed company on the NSE with ticker symbol INDOUS in India, operating in the Process industries sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date27 Sep 2024
  • Listed onNSE: INDOUS
  • Listed entityIndo US Bio-Tech Ltd.
  • Exchange sectorProcess industries
  • ISININE250Z01010
  • Share price₹72.02 (-0.21% on the day) · 2026-10-14
  • Market capitalisation₹144 Cr
  • Price to earnings12.6
  • EPS (diluted, trailing year)₹5.71
  • Volume (last session)5,296

Financials of INDO US BIO-TECH

Exchange-reported figures of Indo Us Bio-Tech Limited, the listed company behind INDO US BIO-TECH (NSE: INDOUS).

Financial Highlights

FY 2021-22 · Consolidated
Revenue
₹50.06 Cr
+24.8% YoY
EBITDA
₹6.79 Cr
+27.4% YoY
Profit After Tax
₹5.06 Cr
+3.3% YoY
Net Worth
₹38.51 Cr
+80.5% YoY
Total Assets
₹52.44 Cr
+55.5% YoY
Total Debt
₹12.84 Cr
+11.0% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue50.0640.1139.76
Revenue growth+24.8%+0.9%-
EBITDA6.795.333.96
EBITDA margin+13.6%+13.3%+10.0%
Profit before tax5.313.922.86
Net profit5.064.902.54
Net profit margin+10.1%+12.2%+6.4%
EPS (₹)5.528.074.18
Balance sheet
Total assets52.4433.7325.68
Net worth38.5121.3416.44
Total debt12.8411.578.58
Cash & bank0.050.130.20
Net working capital43.6728.1622.96
Cash flow
Cash from operations2.700.16(0.84)
Cash from investing(5.44)(1.78)(0.57)
Cash from financing2.651.551.53
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue11010472.8461.7450.0540.0939.76
Revenue growth+6.4%+42.6%+18.0%+23.4%+24.8%+0.8%-
EBITDA17.0118.9310.809.396.955.523.96
EBITDA margin+15.4%+18.2%+14.8%+15.2%+13.9%+13.8%+10.0%
Profit before tax13.9216.528.807.385.494.122.86
Net profit13.1216.268.247.235.245.102.54
Net profit margin+11.9%+15.7%+11.3%+11.7%+10.5%+12.7%+6.4%
EPS (₹)6.548.114.117.225.718.404.18
Balance sheet
Total assets-93.4177.1267.0752.4733.8325.68
Net worth-78.5262.7554.5038.8821.5416.44
Total debt-14.8414.3311.6012.5011.488.58
Cash & bank-0.251.100.190.050.130.20
Net working capital-82.2965.7657.5143.9628.2822.96
Cash flow
Cash from operations-1.422.220.532.910.22(0.84)
Cash from investing-(0.79)(2.53)(6.67)(5.40)(1.75)(0.57)
Cash from financing-(1.48)1.226.292.411.461.53
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue32.9926.0222.8030.8530.7733.3823.5622.17
Revenue growth (YoY)+7.2%-22.1%-3.2%+39.2%+24.5%---
Other income0.120.020.010.030.000.120.020.02
Total expenses29.0322.8018.6526.6825.3028.8018.0217.05
EBITDA3.963.224.154.175.474.585.545.12
EBITDA margin+12.0%+12.4%+18.2%+13.5%+17.8%+13.7%+23.5%+23.1%
Depreciation0.270.270.220.210.200.560.160.18
Interest0.740.600.770.420.450.260.380.52
Profit before tax3.072.373.173.574.823.885.024.44
Tax0.040.410.170.110.120.19(0.04)0.09

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 13 Nov 2026
ParticularsFY 2021-22FY 2020-21FY 2019-20
Revenue50.0640.1139.76
Revenue growth+24.8%+0.9%-
Other income0.180.040.01
Total expenses43.2734.7835.80
Employee cost0.480.330.35
EBITDA6.795.333.96
EBITDA margin+13.6%+13.3%+10.0%
Depreciation0.460.270.23
Interest1.201.180.88
Profit before tax5.313.922.86
Tax0.25(0.97)0.33
Net profit5.064.902.54
Net profit margin+10.1%+12.2%+6.4%
EPS (₹)5.528.074.18
ParticularsFY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital9.176.076.07
Reserves & surplus29.3415.2710.37
Shareholders' funds (net worth)38.5121.3416.44
Minority interest0.000.000.00
Secured loans4.122.510.08
Unsecured loans8.729.068.50
Total debt12.8411.578.58
Total liabilities52.4433.7325.68
Assets
Gross block5.552.371.41
Net block5.552.371.41
Capital work in progress2.321.991.28
Investments0.000.000.00
Inventories23.3611.889.15
Sundry debtors20.5524.7120.98
Cash & bank balances0.050.130.20
Loans & advances2.891.421.58
Total current assets46.8538.1431.91
Total current liabilities3.189.988.95
Net working capital43.6728.1622.96
Total assets52.4433.7325.68
ParticularsFY 2021-22FY 2020-21FY 2019-20
Opening cash0.130.200.08
Net cash from operating activities2.700.16(0.84)
Net cash from investing activities(5.44)(1.78)(0.57)
Net cash from financing activities2.651.551.53
Net change in cash(0.09)(0.07)0.12
Closing cash0.050.130.20
ParticularsFY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+24.8%+0.9%-
EBITDA growth+27.4%+34.6%-
PBT growth+35.5%+37.1%+9997.0%
Net income growth+3.3%+92.9%-
Profitability & leverage
Net income margin+10.1%+12.2%+6.4%
Return on capital employed+15.1%+17.2%+14.6%
Return on net worth+16.9%+25.9%+15.4%
Debt / equity0.410.530.52
Long-term debt / equity0.120.110.05
Interest cover18.9623.3223.59
Efficiency & per share
Fixed asset turnover12.6421.2228.20
Inventory turnover2.843.814.35
Debtors turnover2.211.761.90
EPS (₹)5.528.074.18
Dividend per share (₹)0.000.000.00
Book value per share (₹)42.0135.1727.10
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue32.9926.0222.8030.8530.7733.3823.5622.17
Revenue growth (YoY)+7.2%-22.1%-3.2%+39.2%+24.5%---
Other income0.120.020.010.030.000.120.020.02
Total expenses29.0322.8018.6526.6825.3028.8018.0217.05
EBITDA3.963.224.154.175.474.585.545.12
EBITDA margin+12.0%+12.4%+18.2%+13.5%+17.8%+13.7%+23.5%+23.1%
Depreciation0.270.270.220.210.200.560.160.18
Interest0.740.600.770.420.450.260.380.52
Profit before tax3.072.373.173.574.823.885.024.44
Tax0.040.410.170.110.120.19(0.04)0.09
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue11010472.8461.7450.0540.0939.76
Revenue growth+6.4%+42.6%+18.0%+23.4%+24.8%+0.8%-
Other income0.050.180.320.020.180.040.01
Total expenses93.4384.9162.0452.3543.1034.5735.80
Employee cost0.000.890.931.300.480.340.35
EBITDA17.0118.9310.809.396.955.523.96
EBITDA margin+15.4%+18.2%+14.8%+15.2%+13.9%+13.8%+10.0%
Depreciation0.901.100.800.830.440.260.23
Interest2.241.491.521.201.201.180.88
Profit before tax13.9216.528.807.385.494.122.86
Tax0.800.260.560.150.25(0.97)0.33
Net profit13.1216.268.247.235.245.102.54
Net profit margin+11.9%+15.7%+11.3%+11.7%+10.5%+12.7%+6.4%
EPS (₹)6.548.114.117.225.718.404.18
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital-20.0520.0510.039.176.076.07
Reserves & surplus-58.4742.7044.4729.7115.4710.37
Shareholders' funds (net worth)-78.5262.7554.5038.8821.5416.44
Secured loans-2.212.822.464.122.510.08
Unsecured loans-12.6311.519.148.388.978.50
Total debt-14.8414.3311.6012.5011.488.58
Total liabilities-93.4177.1267.0752.4733.8325.68
Assets
Gross block-14.5310.317.375.542.332.82
Net block-10.236.697.375.542.331.40
Capital work in progress-0.003.781.372.321.991.28
Investments-0.000.000.000.010.010.00
Inventories-70.6951.7426.9123.3611.889.15
Sundry debtors-15.0019.0524.7420.5424.6920.98
Cash & bank balances-0.251.100.190.050.130.20
Loans & advances-0.791.218.073.111.431.58
Total current assets-86.7373.1059.9147.0638.1331.91
Total current liabilities-4.447.342.403.109.858.95
Net working capital-82.2965.7657.5143.9628.2822.96
Total assets-93.4177.1267.0752.4733.8325.68
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash-1.100.190.050.130.200.08
Net cash from operating activities-1.422.220.532.910.22(0.84)
Net cash from investing activities-(0.79)(2.53)(6.67)(5.40)(1.75)(0.57)
Net cash from financing activities-(1.48)1.226.292.411.461.53
Net change in cash-(0.85)0.910.14(0.08)(0.07)0.12
Closing cash-0.251.100.190.050.130.20
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+6.4%+42.6%+18.0%+23.4%+24.8%+0.8%-
EBITDA growth-10.1%+75.3%+15.0%+35.1%+25.9%+39.4%-
PBT growth-15.7%+87.7%+19.2%+34.4%+33.3%+44.1%+1.8%
Net income growth-19.3%+97.3%+14.0%+38.0%+2.8%+100.8%-
Revenue CAGR (3Y)+21.4%+27.5%+22.0%+15.8%+12.3%+10.9%+17.5%
EBITDA CAGR (3Y)+21.9%+39.7%+25.1%+33.4%+26.5%+26.6%+46.9%
Profitability & leverage
Net income margin+11.9%+15.7%+11.3%+11.7%+10.5%+12.7%+6.4%
Return on capital employed-+21.1%+14.3%+14.4%+15.5%+17.9%+16.1%
Return on net worth-+23.0%+14.1%+15.5%+17.4%+26.9%+16.7%
Debt / equity-0.210.220.260.400.530.49
Long-term debt / equity-0.040.040.050.110.110.05
Interest cover13.908.3615.2014.0218.4322.4323.59
Efficiency & per share
Fixed asset turnover-8.368.249.5612.7215.5714.73
Inventory turnover-1.701.852.462.843.814.00
Debtors turnover-6.103.332.732.211.762.65
EPS (₹)6.548.114.117.225.718.404.18
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)0.0039.1631.2954.3542.4135.5027.10

Competitors of INDO US BIO-TECH

INDO US BIO-TECH has 2 listed competitors in our database, 2 of them funded. They include Mahyco and Nuziveedu Seeds.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Mahyco
mahyco.com1991Jalna, India$29.27M
Agriculture company offering hybrid and open pollinated seeds
Nuziveedu Seeds
nuziveeduseeds.com1973Hyderabad, India$104.71M1,258
Improved crop varieties and hybrids are developed and marketed.
Premium access

Detailed competitors of INDO US BIO-TECH

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of INDO US BIO-TECH

The website of INDO US BIO-TECH (indousagriseeds.com) receives about 1.1K visits a month.

  • Monthly visits
    1.1K

    ▲ 26.7% vs previous month

Top companies in Crop Tech & Equipment

3 companies that operate in the same segment as INDO US BIO-TECH (Crop Tech & Equipment) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Ecozen Solutions
Provider of climate-smart deeptech solutions for renewable energy and sustainable agriculture
2010Pune, Maharashtra, IndiaUSD 76.38 MUSD 56.11 M702
Jain Irrigation Systems
Manufacturer and distributor of irrigation equipment
1963Jalgaon, Maharashtra, IndiaUSD 679.04 M2,764
AgroStar
AgroStar is engaged in providing agricultural products and solutions.
2013Pune, Maharashtra, IndiaUSD 208.82 MUSD 104.54 M1,456
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Indo Us Bio-Tech

Indo US Bio-Tech standalone net profit declines 35.32% in the June 2026 quarter | Capital Market News - Business Standard
Business Standard • 3 months ago
Indo Us Bio-Tech Company Receives Summons From Directorate Of Enforcement Under PMLA
Reuters • 10 months ago
Indo US Bio-Tech standalone net profit rises 607.69% in the March 2025 quarter | Capital Market News - Business Standard
Business Standard • 1 year ago
Indo US Bio-Tec Standalone December 2024 Net Sales at Rs 23.56 crore, up 6.56% Y-o-Y
Moneycontrol • 1 year ago
Indo US Bio-Tech to announce Quarterly Result
India Infoline • 1 year ago
Indo US Bio Tech Limited Enters into Rate Contract with Chhattisgarh State Seed and Agriculture Development Corporation Limited
Marketscreener • 3 years ago
Premium access

Complete news archive for INDO US BIO-TECH

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about INDO US BIO-TECH

INDO US BIO-TECH was founded in 2004.

INDO US BIO-TECH is headquartered in Ahmedabad, India. It is registered at Ahmedabad, Gujarat, India.

INDO US BIO-TECH has 22 employees.

The primary company behind INDO US BIO-TECH, Indo Us Bio-Tech Limited, reported revenue of ₹110 Cr for FY 2026, up 6% year on year.

Founded in 2004 in Ahmedabad, India, the company operates in the agriculture sector, focusing on seeds. Research and development, production, marketing, and sales of vegetable seeds, cotton seeds, oilseeds, spice seeds, pulse seeds, and cereal seeds are conducted. Farming guidelines, practices, pest and disease control demonstrations, and fertilizer application advice are also provided to support agricultural activities.

INDO US BIO-TECH's top competitors include Mahyco and Nuziveedu Seeds.

INDO US BIO-TECH offers Tomato Seeds, Okra Seeds, Cotton Seeds, Cucumber Seeds, and Wheat Seeds.

Yes, INDO US BIO-TECH is publicly traded on NSE under the ticker symbol INDOUS.

INDO US BIO-TECH operates through Indo Us Bio-Tech Limited.

The legal entities of INDO US BIO-TECH currently have 8 directors, including Malti Jagdishbhai Ajudia, Jagdishkumar Devjibhai Ajudiya, Priyanka Samarth Patel and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available